Cargando…
Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?
A poor PDAC prognosis is due to a lack of effective treatment and late diagnosis. The early detection of PDAC could significantly decrease mortality and save lives. Idealbiomarkers for PDAC should be cost-effective, detectable in easily accessible biological material, and present in sufficient conce...
Autores principales: | Kapszewicz, Monika, Małecka-Wojciesko, Ewa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619303/ https://www.ncbi.nlm.nih.gov/pubmed/34830745 http://dx.doi.org/10.3390/jcm10225463 |
Ejemplares similares
-
Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors
por: Michalak, Natalia, et al.
Publicado: (2023) -
CA 19-9 but Not IGF-1/IGFBP-2 Is a Useful Biomarker for Pancreatic Ductal Adenocarcinoma (PDAC) and Chronic Pancreatitis (CP) Differentiation
por: Wlodarczyk, Barbara, et al.
Publicado: (2023) -
Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020) -
The microbiome as a potential diagnostic biomarker for pancreatic ductal adenocarcinoma (PDAC)
por: Wheatley, Roseanna C., et al.
Publicado: (2022) -
Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
por: Pervin, Jannat, et al.
Publicado: (2023)